

August 1, 2022

# **Company Report**

■ Change in Estimates | ☑ Target | ☑ Reco

### **Change in Estimates**

	Cur	rent	Prev	/ious
	FY23E	FY24E	FY23E	FY24E
Rating	ACCU	<b>IULATE</b>	В	UY
Target Price	3	00	3	10
Sales (Rs. m)	18,379	19,408	18,379	19,938
% Chng.	-	(2.7)		
EBITDA (Rs. m)	3,430	3,733	3,430	3,899
% Chng.	-	(4.3)		
EPS (Rs.)	13.5	15.3	13.5	16.0
% Chng.	-	(4.6)		

#### **Key Financials - Consolidated**

Y/e Mar	FY21	FY22	FY23E	FY24E
Sales (Rs. m)	9,247	15,713	18,379	19,408
EBITDA (Rs. m)	1,308	2,862	3,430	3,733
Margin (%)	14.1	18.2	18.7	19.2
PAT (Rs. m)	884	1,761	2,253	2,547
EPS (Rs.)	5.3	10.6	13.5	15.3
Gr. (%)	(32.6)	98.8	27.9	13.0
DPS (Rs.)	2.0	3.0	3.4	3.8
Yield (%)	0.7	1.1	1.2	1.4
RoE (%)	7.2	12.9	14.7	14.9
RoCE (%)	7.6	17.4	19.2	18.9
EV/Sales (x)	4.8	2.9	2.4	2.1
EV/EBITDA (x)	33.7	15.8	12.7	11.2
PE (x)	51.3	25.8	20.2	17.9
P/BV (x)	3.5	3.1	2.8	2.5

Key Data	NOCI.BO   NOCIL IN
52-W High / Low	Rs.321 / Rs.191
Sensex / Nifty	58,116 / 17,340
Market Cap	Rs.45bn/ \$ 575m
Shares Outstanding	167m
3M Avg. Daily Value	Rs.308.62m

### **Shareholding Pattern (%)**

Promoter's	33.85
Foreign	2.94
Domestic Institution	4.87
Public & Others	58.34
Promoter Pledge (Rs bn)	-

#### **Stock Performance (%)**

	1M	6M	12M
Absolute	10.2	19.3	4.4
Relative	0.3	20.8	(5.5)

### Nitesh Dhoot

niteshdhoot@plindia.com | 91-22-66322260

# **NOCIL (NOCIL IN)**

Rating: ACCUMULATE | CMP: Rs273 | TP: Rs300

# Domestic volume growth drives strong Q1

#### **Quick Pointers:**

- Volume jump of ~16% YoY in Q1FY23, led by easing supply chain challenges and healthy demand from tyre companies (OEM and replacement market).
- Management indicated 3-6 months delay in attaining full capacity utilization (vs Sep'23 earlier) led by near-term recessionary trends across geographies.

We downgrade NOCIL to 'ACCUMULATE' from BUY, given run up in the stock price over last 2 months and reduction in volume growth estimate driving ~5% EPS reduction for FY24. Despite near term recessionary pressure, NOCIL remains well placed for medium to long term as 1) domestic tyre industry capex is expected to be above Rs.200bn over next 3 years 2) sufficient capacity headroom enables capturing demand improvement 3) moderate competitive intensity with higher environment compliance costs in China leads to better level playing field, plus aligning prices based on changes in RM costs support spreads 4) zero debt balance sheet and healthy FCF generation of Rs.4.4bn over FY23-24E provides comfort, though elevated crude oil (> USD 100/bbl) and increase in supplies by Chinese competition pose risk to volume and spreads in FY23/24. We revise our TP to Rs300 (earlier Rs 310) based on 12x FY24 EV/EBITDA implying 19.5x FY24 EPS of Rs15.3 as we forecast 10% volume CAGR over FY22-24E, tweaking volume estimates slightly to factor delay in full utilization of expanded capacity.

- Strong quarter led by volume jump: Revenue growth of 48% YoY/ 10% QoQ on healthy volume growth of 16% YoY/ 11% QoQ, with improved realisations up 27%YoY (flat QoQ). Volume growth was driven by domestic market on healthy lifting from tyre companies with improvement in OEM and replacement market demand. Export revenue contribution stood at ~32% in Q1 (vs 36% in FY22). Gross margin declined to 46.4% (-300bps YoY) despite expansion in spreads, due to higher ASP's (denominator effect). EBITDA stood at Rs1.0bn (+40% YoY/ -8% QoQ) on strong volume growth while EBTDA margin was 20.2% (-110bps YoY/ -390bps QoQ) on lower gross margins and higher overheads/ utility costs (+46% YoY). PAT +40% YoY/-3.5% QoQ to Rs.665mn.
- Concall takeaways: (1) Management highlighted that interactions with customers suggest slower demand across geographies in coming months (2) H1FY23 volume growth guidance at ~10% YoY (3) Capacity utilization in Q1 was ~75% in Q1FY23 (inventory build-up in Q4FY22 aided vol growth in Q1). (4) Company to undertake debottlenecking for select products over next year to meet demand growth post current capacity reaching full utilization, while longer term capex to be evaluated simultaneously (5) Land at Dahej is utilized at ~50-60% and there is scope for brownfield expansion (6) Global rubber consumption increased 10.6% in CY21 on lower base of -6.7% in CY20. (7) Exports contributed 32% to company's revenue in Q1FY23 and it targets ~40% contribution for the long term (growth from existing and new customers) (8) NOCIL's domestic market share is at ~42% and likely to be maintained (9) RM prices were largely flattish in Q1 with some exceptions in domestic market. It is difficult to predict RM prices given global disturbances.

August 1, 2022




Exhibit 1: Q1FY23 Result Overview - Consolidated (Rs mn)

Y/e March	Q1FY23	Q1FY22	YoY gr.	Q4FY22	QoQ gr.
Net Revenue	5,089	3,445	47.7%	4,627	10.0%
Material Cost	2,726	1,742	56.5%	2,311	18.0%
Gross Profit	2,363	1,703	38.8%	2,317	2.0%
Gross Margin (%)	46.4%	49.4%		50.1%	
Employee expenses	240	217	10.7%	202	19.0%
Other operating expenses	1,097	752	45.9%	1,001	9.7%
EBITDA	1,026	734	39.7%	1,114	-7.9%
EBITDA margin (%)	20.2%	21.3%		24.1%	
Depreciation	137	105	29.9%	163	-16.0%
EBIT	889	629	41.4%	951	-6.5%
Other income	11	11	-5.4%	12	-13.2%
Interest cost	3	2	21.7%	4	-28.2%
PBT	897	638	40.7%	959	-6.5%
Tax	232	164	41.9%	270	-14.1%
Sh of ass. / Minority int	0	0		0	
PAT	665	474	40.2%	689	-3.5%
Extra ordinary income/ (exp.)	0	0		0	
Adjusted PAT	665	474	40.2%	689	-3.5%
Adj. PAT margin (%)	13.1%	13.8%		14.9%	
No. of shares (mn)	167	166	0.1%	167	0.0%
Adj. EPS (Rs.)	4.0	2.8	40.1%	4.1	-3.5%


Source: Company, PL

Exhibit 2: Strong quarter led by domestic volume growth




Source: Company, PL

Exhibit 3: Healthy margins on pass through of higher costs




Source: Company, PL

Exhibit 4: Rev to grow at 11% CAGR (FY22-24E) led by vol




Source: Company, PL

Exhibit 5: Margin improvement on op. leverage benefits




Source: Company, PL

Exhibit 6: Vol growth aided by demand traction




Source: Company, PL

Exhibit 7: Healthy recovery in global rubber consumption




Source: Company, PL

Exhibit 8: Steady profits with negligible capex to boost FCF



Source: Company, PL


Exhibit 9: Net cash BS with improving return ratios



Source: Company, PL




Exhibit 10: P/E Band (1 year forward)



Source: Company, PL

Exhibit 11: EV/EBITDA Band (1 year forward)



Source: Company, PL



# **Financials**

Income Statement	(Rs m)
------------------	--------

Y/e Mar	FY21	FY22	FY23E	FY24E
Net Revenues	9,247	15,713	18,379	19,408
YoY gr. (%)	9.3	69.9	17.0	5.6
Cost of Goods Sold	5,046	8,593	9,987	10,551
Gross Profit	4,200	7,120	8,392	8,857
Margin (%)	45.4	45.3	45.7	45.6
Employee Cost	701	808	882	951
Other Expenses	2,192	3,450	4,080	4,173
EBITDA	1,308	2,862	3,430	3,733
YoY gr. (%)	(26.6)	118.8	19.9	8.8
Margin (%)	14.1	18.2	18.7	19.2
Depreciation and Amortization	374	483	495	507
EBIT	934	2,378	2,935	3,226
Margin (%)	10.1	15.1	16.0	16.6
Net Interest	10	11	-	-
Other Income	147	39	78	178
Profit Before Tax	1,071	2,406	3,012	3,405
Margin (%)	11.6	15.3	16.4	17.5
Total Tax	187	645	759	858
Effective tax rate (%)	17.5	26.8	25.2	25.2
Profit after tax	884	1,761	2,253	2,547
Minority interest	-	-	-	-
Share Profit from Associate	-	=	-	-
Adjusted PAT	884	1,761	2,253	2,547
YoY gr. (%)	(32.3)	99.2	27.9	13.0
Margin (%)	9.6	11.2	12.3	13.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	884	1,761	2,253	2,547
YoY gr. (%)	(32.3)	99.2	27.9	13.0
Margin (%)	9.6	11.2	12.3	13.1
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	884	1,761	2,253	2,547
Equity Shares O/s (m)	166	167	167	167
EPS (Rs)	5.3	10.6	13.5	15.3

Source: Company Data, PL Research

**Balance Sheet Abstract (Rs m)** 

Y/e Mar	FY21	FY22	FY23E	FY24E
Non-Current Assets				
Gross Block	11,830	12,231	12,531	12,831
Tangibles	11,742	12,119	12,419	12,719
Intangibles	88	112	112	112
Acc: Dep / Amortization	2,658	3,142	3,637	4,144
Tangibles	2,582	3,065	3,560	4,068
Intangibles	77	77	77	77
Net fixed assets	9,172	9,090	8,894	8,687
Tangibles	9,160	9,054	8,859	8,651
Intangibles	12	36	36	36
Capital Work In Progress	141	84	84	84
Goodwill	-	-	-	-
Non-Current Investments	494	599	599	599
Net Deferred tax assets	(995)	(1,068)	(1,068)	(1,068)
Other Non-Current Assets	113	94	94	94
Current Assets				
Investments	435	176	176	176
Inventories	1,657	3,327	3,684	3,890
Trade receivables	3,086	4,498	5,035	5,317
Cash & Bank Balance	804	160	1,797	3,592
Other Current Assets	161	133	155	164
Total Assets	16,146	18,305	20,688	22,782
Equity				
Equity Share Capital	1,662	1,666	1,666	1,666
Other Equity	11,185	12,786	14,476	16,386
Total Networth	12,847	14,452	16,142	18,052
Non-Current Liabilities				
Long Term borrowings	-	-	-	-
Provisions	161	164	164	164
Other non current liabilities	39	29	29	29
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	1,703	2,151	2,769	2,925
Other current liabilities	401	442	517	545
Total Equity & Liabilities	16,146	18,305	20,688	22,782

Source: Company Data, PL Research



Cash Flow (Rs m)						
Y/e Mar	FY21	FY22	FY23E	FY24E		
PBT	1,071	2,406	3,012	3,405		
Add. Depreciation	374	483	495	507		
Add. Interest	10	11	-	-		
Less Financial Other Income	147	39	78	178		
Add. Other	(134)	(46)	(78)	(178)		
Op. profit before WC changes	1,321	2,855	3,430	3,733		
Net Changes-WC	(382)	(2,560)	(256)	(326)		
Direct tax	(4)	(597)	(751)	(855)		
Net cash from Op. activities	936	(302)	2,423	2,553		
Capital expenditures	(265)	(362)	(300)	(300)		
Interest / Dividend Income	16	17	78	178		
Others	(371)	657	-	-		
Net Cash from Invt. activities	(621)	312	(222)	(122)		
Issue of share cap. / premium	37	29	-	-		
Debt changes	-	-	-	-		
Dividend paid	(7)	(332)	(563)	(637)		
Interest paid	(10)	(11)	-	-		
Others	20	(23)	-	-		
Net cash from Fin. activities	40	(336)	(563)	(637)		
Net change in cash	355	(327)	1,638	1,795		
Free Cash Flow	666	(664)	2,123	2,253		

Source: Company Data, PL Research

Quarterly Financials (Rs m)

Y/e Mar	Q2FY22	Q3FY22	Q4FY22	Q1FY23
Net Revenue	3,752	3,889	4,627	5,089
YoY gr. (%)	69.3	41.6	43.7	47.7
Raw Material Expenses	2,231	2,310	2,311	2,726
Gross Profit	1,521	1,579	2,317	2,363
Margin (%)	40.5	40.6	50.1	46.4
EBITDA	503	508	1,114	1,026
YoY gr. (%)	57.4	33.2	112.9	39.7
Margin (%)	13.4	13.0	24.1	20.2
Depreciation / Depletion	107	108	163	137
EBIT	396	399	951	889
Margin (%)	10.6	10.3	20.6	17.5
Net Interest	2	3	4	3
Other Income	14	5	12	11
Profit before Tax	408	401	959	897
Margin (%)	10.9	10.3	20.7	17.6
Total Tax	108	104	270	232
Effective tax rate (%)	26.5	25.8	28.2	25.9
Profit after Tax	300	298	689	665
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
Adjusted PAT	300	298	689	665
YoY gr. (%)	78.3	33.5	84.6	40.2
Margin (%)	8.0	7.7	14.9	13.1
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	300	298	689	665
YoY gr. (%)	78.3	33.5	84.6	40.2
Margin (%)	8.0	7.7	14.9	13.1
Other Comprehensive Income	76	-	(18)	23
Total Comprehensive Income	376	298	672	688
Avg. Shares O/s (m)	166	167	167	167
EPS (Rs)	1.8	1.8	4.1	4.0

Source: Company Data, PL Research

(e)	/ F	ınar	ıcıaı	Metr	ICS

Y/e Mar	FY21	FY22	FY23E	FY24E
Per Share(Rs)				
EPS	5.3	10.6	13.5	15.3
CEPS	7.6	13.5	16.5	18.3
BVPS	77.3	86.8	96.9	108.4
FCF	4.0	(4.0)	12.7	13.5
DPS	2.0	3.0	3.4	3.8
Return Ratio(%)				
RoCE	7.6	17.4	19.2	18.9
ROIC	6.7	13.5	15.5	17.0
RoE	7.2	12.9	14.7	14.9
Balance Sheet				
Net Debt : Equity (x)	(0.1)	0.0	(0.1)	(0.2)
Net Working Capital (Days)	120	132	118	118
Valuation(x)				
PER	51.3	25.8	20.2	17.9
P/B	3.5	3.1	2.8	2.5
P/CEPS	36.1	20.3	16.5	14.9
EV/EBITDA	33.7	15.8	12.7	11.2
EV/Sales	4.8	2.9	2.4	2.1
Dividend Yield (%)	0.7	1.1	1.2	1.4

Source: Company Data, PL Research

# **Key Operating Metrics**

Y/e Mar	FY21	FY22	FY23E	FY24E
Sales Volume Growth (%)	14.0	16.0	10.0	10.0
Avg Realisations Growth (%)	(4.4)	48.4	5.0	(4.0)
Exports Contribution (%)	32.7	36.0	38.5	40.1
Capex (Rs bn)	0.3	0.4	0.3	0.3

Source: Company Data, PL Research





No.	Date	Rating	TP (Rs.) Share Pric	e (Rs.)
1	06-Jul-22	BUY	310	252
2	19-May-22	BUY	310	255
3	08-Apr-22	BUY	285	242
4	07-Feb-22	BUY	270	229

**Recommendation History** 

### **Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Aarti Industries	Accumulate	880	685
2	Fine Organic Industries	BUY	5,600	4,950
3	NOCIL	BUY	310	252

## PL's Recommendation Nomenclature (Absolute Performance)

 Buy
 : > 15%

 Accumulate
 : 5% to 15%

 Hold
 : +5% to -5%

 Reduce
 : -5% to -15%

 Sell
 : < -15%</td>

Not Rated (NR) : No specific call on the stock
Under Review (UR) : Rating likely to change shortly



### **ANALYST CERTIFICATION**

### (Indian Clients)

We/l, Mr. Nitesh Dhoot- B.Com (Hons), MBA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### (US Clients)

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

### **DISCLAIMER**

#### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Nitesh Dhoot- B.Com (Hons), MBA Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

### Prabhudas Lilladher Pvt. Ltd.

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 www.plindia.com